Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 01/12 10:00:01 pm
79.02 USD   -0.05%
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE F : Icer
01/12 Respiratory Syncytial Virus Infections– Unmet Needs in Adul..
Analysis summary4-Traders Strategies

Continuation of the bullish trend

share with twitter share with LinkedIn share with facebook
share via e-mail
08/27/2014 | 04:00pm

Gilead Sciences is trading in a bullish trend and several arguments are in favor of the continuation of this trend.

From a fundamental viewpoint, the company is strong. The Thomson Reuters consensus regularly revised upward sales and EPS estimates of the company for the next two years. The YM Biosciences acquisition in 2013 permits the group to considerably improve its sales and earnings. Thanks to this event, EPS should rise from USD 1.81 in 2013 to USD 7.33 in 2014. Moreover, the company benefits from attractive valuation levels compared to its peers, with a P/E ratio at 14.7x for the current fiscal year.

Technical patterns are in the green: prices are up for several months, and the stock follows a bullish trend as shown by the trendline. Prices are currently testing their USD 107.5 midterm resistance, and the crossing of this threshold would be a bullish signal. The moving averages' orientation, particularly the 20-day one should help to reach the USD 119 long term resistance.

According to both technical and fundamental elements, it seems opportune to take a long position at the current price. The bullish trend should allow the security to reach the USD 119 resistance. If the stock crosses it, a new target price will be set. A stop loss will be placed under the entry point to avoid a downtrend.

Clémence Floquet
© Zonebourse.com 2014
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2017 25 804 M
EBIT 2017 15 658 M
Net income 2017 10 508 M
Debt 2017 12 756 M
Yield 2017 2,67%
P/E ratio 2017 10,18
P/E ratio 2018 13,41
EV / Sales 2017 4,49x
EV / Sales 2018 5,10x
Capitalization 103 B
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Duration : Period : Day
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Duration : Period : Week
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders